Show simple item record

dc.contributor.authorIrazoqui, Javier E
dc.date2022-08-11T08:09:18.000
dc.date.accessioned2022-08-23T16:26:10Z
dc.date.available2022-08-23T16:26:10Z
dc.date.issued2020-02-01
dc.date.submitted2020-03-13
dc.identifier.citation<p>Trends Immunol. 2020 Feb;41(2):157-171. doi: 10.1016/j.it.2019.12.003. Epub 2020 Jan 17. <a href="https://doi.org/10.1016/j.it.2019.12.003">Link to article on publisher's site</a></p>
dc.identifier.issn1471-4906 (Linking)
dc.identifier.doi10.1016/j.it.2019.12.003
dc.identifier.pmid31959514
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36508
dc.description.abstractMicrophthalmia/TFE (MiT) transcription factors (TFs), such as transcription factor EB (TFEB) and transcription factor E3 (TFE3), are emerging as key regulators of innate immunity and inflammation. Rapid progress in the field requires a focused update on the latest advances. Recent studies show that TFEB and TFE3 function in innate immune cells to regulate antibacterial and antiviral responses downstream of phagocytosis, interferon (IFN)-gamma, lipopolysaccharide (LPS), and adenosine receptors. Moreover, overexpression of TFEB or TFE3 can drive inflammation in vivo, such as in atherosclerosis, while in other scenarios they can perform anti-inflammatory functions. MiT factors may constitute potential therapeutic targets for a broad range of diseases; however, to harness their therapeutic potential, sophisticated ways to manipulate MiT factor activity safely and effectively must be developed.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31959514&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1016/j.it.2019.12.003
dc.subjectTFEB
dc.subjectTFE3
dc.subjecttranscription
dc.subjectinflammation
dc.subjectinnate immunity
dc.subjectinfection
dc.subjectImmunology and Infectious Disease
dc.subjectMicrobiology
dc.titleKey Roles of MiT Transcription Factors in Innate Immunity and Inflammation
dc.typeJournal Article
dc.source.journaltitleTrends in immunology
dc.source.volume41
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/maps_pubs/69
dc.identifier.contextkey16817183
html.description.abstract<p>Microphthalmia/TFE (MiT) transcription factors (TFs), such as transcription factor EB (TFEB) and transcription factor E3 (TFE3), are emerging as key regulators of innate immunity and inflammation. Rapid progress in the field requires a focused update on the latest advances. Recent studies show that TFEB and TFE3 function in innate immune cells to regulate antibacterial and antiviral responses downstream of phagocytosis, interferon (IFN)-gamma, lipopolysaccharide (LPS), and adenosine receptors. Moreover, overexpression of TFEB or TFE3 can drive inflammation in vivo, such as in atherosclerosis, while in other scenarios they can perform anti-inflammatory functions. MiT factors may constitute potential therapeutic targets for a broad range of diseases; however, to harness their therapeutic potential, sophisticated ways to manipulate MiT factor activity safely and effectively must be developed.</p>
dc.identifier.submissionpathmaps_pubs/69
dc.contributor.departmentProgram in Innate Immunity
dc.contributor.departmentDepartment of Microbiology and Physiological Systems
dc.source.pages157-171


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record